Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising results," Robert M. Jotte, M.D., Ph.D., principal investigator of the study, director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and developmental co-chair of US Oncology Lung Committee, said. "These results support the ongoing drive toward using personalized health care to dictate therapy in an attempt to optimize outcomes. A follow-up study to advance the combination toward registration is planned."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... ... a residential inpatient rehabilitation center can find some useful information in a new ... in Central Michigan. This video, which can be viewed on the Serenity Recovery ...
(Date:5/2/2016)... ... 2016 , ... Beanfields, PBC, makers of Beanfields Bean and ... at University of Colorado in Boulder to create new advertising campaigns. , Adjunct ... School of Journalism, who selected Beanfields as the brand on which to focus ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... In ... will offer an incentive to people who share their fitness journey on social ... and premium first aid products, will award a $100 product voucher each week during ...
(Date:5/2/2016)... ... 2016 , ... East Los Angeles dentist , Dr. Ramin Assili, is ... to receive any dental extraction treatment for $40 off the regular price. This promotion ... the lower price, patients can more easily afford extractions to eliminate teeth that are ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt ... of cloud-based software solutions for life sciences, today announced key new ... wealth of insight to a growing business.  This will bolster the ... George Phillips joined ArisGlobal in the position of Vice President ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
Breaking Medicine Technology: